UK life sciences sector leaders are pleased to have attracted Flagship Pioneering to invest in the country, as its CEO Noubar Afeyan emphasizes that its initial focus would be on early ‘experiments’ in innovation and cultural bridge-building.

Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.

Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.

As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.